Search results for: Generics
Filter search results
Estimating US Savings from Biosimilars
13 July 2010
…growth hormone or rheumatoid arthritis products. In addition, a key driver of market penetration for small-molecule generics, the pharmacist, will have far less impact on biologics, both because of current…
Price Competition and Biosimilars
23 June 2010
Virtually all models forecast that price competition will be less intense and price declines modest in comparison to the generics model. Many models, however, miss or underestimate factors and trends…
The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance
12 October 2022
…antibiotics [2]. Coupled with the fact that many of those existing antibiotics are low-cost generics, companies don’t have the evidence to demonstrate the added clinical value or cost-effectiveness of a…
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
…drugs at prices close to those of generics, facilitating greater patient access and placing less strain on budgets. Additional reward payments would then be made over the course of a…
Dr. Sabine Vogler
4 September 2024
…Open, of the Generics and Biosimilars Initiative (GaBI) journal and of the International Advisory Board of the Pharmaceutical Policy and Practice (JOPPP) journal as well as an Associate Editor of…
The Market for Biosimilars: Evolution and Policy Options
1 November 2008
…differences mean that biosimilar markets will evolve in a more complex way than traditional, small molecule, chemical generics markets. Regulators will need clinical trial evidence of efficacy and safety before…
Drug shortages are on the rise – but what is their impact?
16 September 2024
…consideration must be given to the downstream impact this may cause to vulnerable supply chains and higher risks of shortages, particularly in the generics and biosimilars market which already only…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…for generics and biosimilars. Accounting for all these benefits from generic/biosimilar competition in the UP scenario (and for a 100-year time horizon) is unrealistic. The modelling contains naïve assumptions about…
Biosimilars: Modelling the Evolution of the Market
16 June 2010
…of Prof Adrian Towse and Dr Jorge Mestre-Ferrandiz. Describing and/or forecasting the market for biosimilars must first recognize that these products are not identical, i.e., not ‘biogenerics.’ This affects both…